Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response

Abstract

Objective

Hepatocellular carcinoma (HCC) presents substantial genetic and phenotypic diversity, making it challenging to predict patient outcomes. There is a clear need for novel biomarkers to better identify high-risk individuals. Long non-coding RNAs (lncRNAs) are known to play key roles in cell cycle regulation and genomic stability, and their dysregulation has been closely linked to HCC progression. Developing a prognostic model based on cell cycle-related lncRNAs could open up new possibilities for immunotherapy in HCC patients.

Methods

Transcriptomic data and clinical samples were obtained from the TCGA-HCC dataset. Cell cycle-related gene sets were sourced from existing studies, and coexpression analysis identified relevant lncRNAs (correlation coefficient >0.4, P<0.001). Univariate analysis identified prognostic lncRNAs, which were then used in a LASSO regression model to create a risk score. This model was validated via cross-validation. HCC samples were classified on the basis of their risk scores. Correlations between the risk score and tumor mutational burden (TMB), tumor immune infiltration, immune checkpoint gene expression, and immunotherapy response were evaluated via R packages and various methods (TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCP-COUNTER, XCELL, and EPIC).

Results

Four cell cycle-related lncRNAs (AC009549.1, AC090018.2, PKD1P6-NPIPP1, and TMCC1-AS1) were significantly upregulated in HCC. These lncRNAs were used to create a risk score (risk score=0.492×AC009549.1+1.390×AC090018.2+1.622×PKD1P6-NPIPP1+0.858×TMCC1-AS1). This risk score had superior predictive value compared to traditional clinical factors (AUC=0.738). A nomogram was developed to illustrate the 1-year, 3-year, and 5-year overall survival (OS) rates for individual HCC patients. Significant differences in TMB, immune response, immune cell infiltration, immune checkpoint gene expression, and drug responsiveness were observed between the high-risk and low-risk groups.

Conclusion

The risk score model we developed enhances the prognostication of HCC patients by identifying those at high risk for poor outcomes. This model could lead to new immunotherapy strategies for HCC patients.

References

[1] IoannouGN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol, 2021, 75(6): 1476-1484

[2] KanwalF, KramerJR, MapakshiS, et al. . Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2018, 155(6): 1828-1837.e2

[3] AtiqO, TiroJ, YoppAC, et al. . An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology, 2017, 65(4): 1196-1205

[4] ChoiJ, KimGA, HanS, et al. . Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. Hepatology, 2019, 69(5): 1983-1994

[5] ToyodaH, KumadaT, TadaT, et al. . Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci, 2011, 102(5): 1025-1031

[6] ZhouJ, YuL, GaoX, et al. . Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 2011, 29(36): 4781-4788

[7] SlackFJ, ChinnaiyanAM. The Role of Non-coding RNAs in Oncology. Cell, 2019, 179(5): 1033-1055

[8] YuanW, SunY, LiuL, et al. . Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma. Cell Physiol Biochem, 2017, 44(1): 125-132

[9] TangJC, FengYL, GuoT, et al. . Circulating tumor DNA in hepatocellular carcinoma: trends and challenges. Cell Biosci, 2016, 6: 32

[10] CalderaroJ, CouchyG, ImbeaudS, et al. . Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol, 2017, 67(4): 727-738

[11] SchulzeK, ImbeaudS, LetouzéE, et al. . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet, 2015, 47(5): 505-511

[12] JiangP, SunK, TongYK, et al. . Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci U S A, 2018, 115(46): E10925-E10933

[13] JiangP, ChanCW, ChanKC, et al. . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A, 2015, 112(11): E1317-E1325

[14] ShengLQ, LiJR, QinH, et al. . Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis. World J Gastrointest Oncol, 2020, 12(10): 1195-1208

[15] JohnsonPJ, PirrieSJ, CoxTF, et al. . The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev, 2014, 23(1): 144-153

[16] LambrechtsD, WautersE, BoeckxB, et al. . Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med, 2018, 24(8): 1277-1289

[17] OzgaAJ, ChowMT, LusterAD. Chemokines and the immune response to cancer. Immunity, 2021, 54(5): 859-874

[18] MontanariNR, AnugwomCM, BoonstraA, et al. . The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel), 2021, 13(19): 4876

[19] AddeoA, FriedlaenderA, BannaGL, et al. . TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol, 2021, 163: 103374

[20] JiangP, GuS, PanD, et al. . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med, 2018, 24(10): 1550-1558

[21] IasonosA, SchragD, RajGV, et al. . How to build and interpret a nomogram for cancer prognosis. J Clin Oncol, 2008, 26(8): 1364-1370

[22] WangY, ZhangY, WangL, et al. . Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC. Hepatol Int, 2022, 16(6): 1435-1447

[23] HoshidaY, VillanuevaA, KobayashiM, et al. . Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med, 2008, 359(19): 1995-2004

[24] HuangZ, ZhouJK, PengY, et al. . The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer, 2020, 19(1): 77

[25] LiuPH, HsuCY, HsiaCY, et al. . Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol, 2016, 64(3): 601-608

[26] ZhaoQJ, ZhangJ, XuL, et al. . Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol, 2018, 24(30): 3426-3439

[27] XuS, ZhouY, LuoJ, et al. . Integrated Analysis of a Ferroptosis-Related LncRNA Signature for Evaluating the Prognosis of Patients with Colorectal Cancer. Genes (Basel), 2022, 13(6): 1094

[28] DengX, BiQ, ChenS, et al. . Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. Front Mol Biosci, 2020, 7: 611626

[29] ChenJ, JiaX, LiZ, et al. . Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma. Biochem Pharmacol, 2021, 188: 114494

[30] CuiH, ZhangY, ZhangQ, et al. . A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. Cancer Med, 2017, 6(12): 2932-2941

[31] HongW, LiangL, GuY, et al. . Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids, 2020, 22: 937-947

[32] RufB, HeinrichB, GretenTF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol, 2021, 18(1): 112-127

[33] PanG, ZhangJ, YouF, et al. . ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1. Bioengineered, 2022, 13(1): 1346-1358

[34] ZhengJ, ShaoM, YangW, et al. . Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Int Immunopharmacol, 2022, 112: 109244

[35] XieF, BaiY, YangX, et al. . Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. Int Immunopharmacol, 2020, 89: 107135 Pt A

[36] McgrailDJ, PiliéPG, RashidNU, et al. . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol, 2021, 32(5): 661-672

[37] KimH, HongJY, LeeJ, et al. . Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol, 2021, 13: 1758835921992992

[38] ValeroC, LeeM, HoenD, et al. . The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet, 2021, 53(1): 11-15

[39] SangroB, MeleroI, WadhawanS, et al. . Association of inflammatory biomarkers with clinical outcomes in nivolumabtreated patients with advanced hepatocellular carcinoma. J Hepatol, 2020, 73(6): 1460-1469

[40] HodiFS, WolchokJD, SchadendorfD, et al. . TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunol Res, 2021, 9(10): 1202-1213

[41] ZhangQ, HeY, LuoN, et al. . Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell, 2019, 179(4): 829-845.e20

[42] LurjeI, HammerichL, TackeF. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci, 2020, 21(19): 7378

[43] WiedemannGM, KnottMM, VetterVK, et al. . Cancer cell-derived IL-1a induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology, 2016, 5(9): e1175794

[44] OuyangFZ, WuRQ, WeiY, et al. . Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. Nat Commun, 2016, 7: 13453

[45] NewmanAM, LiuCL, GreenMR, et al. . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015, 12(5): 453-457

[46] SongM, HeJ, PanQZ, et al. . Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. Hepatology, 2021, 73(5): 1717-1735

[47] LuoQ, WangCQ, YangLY, et al. . FOXQ1/NDRG1 axis exacerbates hepatocellular carcinoma initiation via enhancing crosstalk between fibroblasts and tumor cells. Cancer Lett, 2018, 417: 21-34

[48] CaiL, ZhangZ, ZhouL, et al. . Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol, 2008, 129(3): 428-437

[49] ChewV, ChenJ, LeeD, et al. . Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut, 2012, 61(3): 427-438

[50] WangQ, QinY, LiB. CD8(+) T cell exhaustion and cancer immunotherapy. Cancer Lett, 2023, 559: 216043

[51] BroersenLH, Van PeltGW, TollenaarRA, et al. . Clinical application of circulating tumor cells in breast cancer. Cell Oncol (Dordr), 2014, 37(1): 9-15

[52] ZhengX, ZhangY, WangY, et al. . Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients. Front Surg, 2023, 10: 1052100

[53] LiangJY, WangDS, LinHC, et al. . A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci, 2020, 16(13): 2430-2441

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology